FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83909
News▲ Bullish
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A sizable biotech IPO signals investor appetite for RNAi platforms, supporting sector sentiment.
Biotech IPO window shows appetite
CATALYST TO WATCH
Post-IPO trading performance
MAIN RISK
Single IPO, not sector-wide
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
→CORRELATIONshares XBI, Healthcare
Iambic Therapeutics raises USD 150m in Nasdaq IPO2026-10-16 10:24 UTC
Iambic Therapeutics raises USD 150m in Nasdaq IPO2026-10-16 10:24 UTC
→CORRELATIONshares Healthcare
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
←CORRELATIONshares Healthcare
A stock sale is expected to bring City Therapeutics about $200 million.2026-10-16 02:37 UTC
A stock sale is expected to bring City Therapeutics about $200 million.2026-10-16 02:37 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.